Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leucine-rich repeat-containing 8 VRAC subunit A (LRRC8A)
- Target
- LRRC8A
- Molecular classification
- Ion channel, Volume-regulated anion channel (VRAC) subunit
01
Overview
Leucine-rich repeat-containing 8 VRAC subunit A (LRRC8A) is a transmembrane protein essential for the formation and function of the volume-regulated anion channel (VRAC), which is crucial for maintaining cellular homeostasis under osmotic stress by mediating chloride and organic osmolyte flux. LRRC8A forms heteromeric channels with other LRRC8 family members, and its expression and assembly affect the specificity and efficiency of VRAC activity. Beyond volume regulation, LRRC8A regulates immune cell development, modulates signaling molecule release, and is implicated in disease processes including cancer metastasis, chemoresistance, and congenital immune deficiencies. Structural studies show LRRC8A contains a pore domain and a leucine-rich repeat domain, both critical for channel function and regulation.
- Other names
- LRRC8ASWELL1leucine-rich repeat containing 8 family member AAGM5LRRC8leucine rich repeat containing 8 VRAC subunit AHsLRRC8A
02
Mechanism of action
For cisplatin: LRRC8A regulates cisplatin-induced activation of p53 and downstream signaling involving p21, influencing cell cycle arrest and apoptosis. Potential: direct channel blockers would inhibit chloride/osmolyte flux and volume regulation.
03
Biological functions
Cell volume regulationTransport of chloride and organic osmolytes (e.g., taurine, glutamate)Release and uptake of signaling molecules (e.g., cyclic dinucleotides, glutamate)Modulation of synaptic efficacyT cell development and survivalImmune response (including interferon-potentiation during viral infection)
04
Disease associations
Cancer (implicated in cell proliferation, migration, chemoresistance, and metastasis)Immunodeficiency (e.g., agammaglobulinemia-5, B cell development defects, T cell development block)Neurological contexts (affecting astrocyte signaling, synaptic function)
05
Safety considerations
Inhibition or dysfunction can cause immune system defects (agammaglobulinemia, impaired thymocyte development, decreased proliferation, apoptosis)Dysregulated LRRC8A activity may contribute to cancer cell chemoresistance and metastasis
06
Interacting drugs
Cisplatin
07
Biomarkers
LRRC8A protein expression may serve as a biomarker for cell volume regulation status, certain immunodeficiencies (agammaglobulinemia-5), and cancer progression or chemoresistance
Beyond the preview
Go deeper on Leucine-rich repeat-containing 8 VRAC subunit A (LRRC8A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leucine-rich repeat-containing 8 VRAC subunit A (LRRC8A).